Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications
Journal of Personalized Medicine · 06.05.2026 · 16 (5) · 254
DOI: 10.3390/jpm16050254 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 06.05.2026. Verfasst von Abdelrahman Hafez und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Coronary microvascular dysfunction (CMD) has emerged as a crucial contributor to cardiovascular morbidity and mortality, particularly in patients with ischemia and non-obstructive coronary arteries (INOCA). The condition arises from a complex interplay of structural and functional abnormalities within the small coronary vessels, driven by underlying molecular mechanisms including endothelial nitric oxide synthase (eNOS) uncoupling, oxidative stress, and chronic inflammation. Lipid metabolism plays a central role in this pathology, especially in the setting of elevated low-density lipoprotein cholesterol (LDL-C). Furthermore, the protective capacity of high-density lipoprotein (HDL) is increasingly understood to depend on its functionality rather than absolute levels, as it can become dysfunctional and pro-inflammatory in pathological states. Emerging evidence has identified lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins as significant, independent contributors to microvascular injury. Comprehensive clinical assessment of microvascular dysfunction therefore requires integration of advanced lipid profiling, including apolipoprotein B (ApoB), [Lp(a)], and the triglyceride-glucose (TyG) index with invasive and non-invasive measures of coronary flow reserve to more precisely stratify risk. In this narrative review, we synthesize current observational, mechanistic, and early interventional data linking diverse lipid phenotypes to coronary microvascular dysfunction. We propose a concept of lipid-driven CMD endotypes, such as ApoB-/particle overload, dysfunctional HDL, Lp(a)-mediated risk, and metabolic/TyG-high states, and map these to a practical, mechanism-informed management framework. While intensive LDL-C lowering with high-intensity statins and combination therapy remains guideline-directed care for high-risk patients, evidence for dedicated microvascular benefit from newer lipid and cardiometabolic agents is still largely hypothesis-generating. A personalized approach that aligns lipid phenotyping, CMD endotyping, and existing guideline-based therapies may help refine risk assessment and inform future trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
ORCID-Profile: Abdelrahman Hafez, Juan M Farina, Milagros Pereyra Pietri, Isabel G Scalia, Hesham Sheashaa, Fatmaelzahraa E Abdelfattah, Mahshad Razaghi, Reza Arsanjani
Zitieren
APA
Hafez, A., Farina, J. M., Awad, K., Pietri, M. P., Scalia, I. G., Sheashaa, H., Abdelfattah, F. E., Razaghi, M., Ahmed, S., Ibrahim, R., Simper, D., Lester, S. J., Tamarappoo, B., Ayoub, C., & Arsanjani, R. (2026). Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications. Journal of Personalized Medicine, 16(5), 254. https://doi.org/10.3390/jpm16050254
Vancouver
Hafez A, Farina JM, Awad K, Pietri MP, Scalia IG, Sheashaa H, et al. Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications. Journal of Personalized Medicine. 2026;16(5):254. doi:10.3390/jpm16050254
BibTeX
@article{Hafez2026,
author = {Hafez, Abdelrahman and Farina, Juan M and Awad, Kamal and Pietri, Milagros Pereyra and Scalia, Isabel G and Sheashaa, Hesham and Abdelfattah, Fatmaelzahraa E and Razaghi, Mahshad and Ahmed, Sherif and Ibrahim, Ramzi and Simper, David and Lester, Steven J and Tamarappoo, Balaji and Ayoub, Chadi and Arsanjani, Reza},
title = {Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {5},
pages = {254},
doi = {10.3390/jpm16050254}
}
EUVIMED